IDEAYA Biosciences
IDYA
IDEAYA Biosciences (IDYA) news
Recent news
IDEAYA Biosciences, Inc.: Stifel resumes coverage with buy rating; price target $48
AInvest Wire · 2d agoIDEAYA Biosciences announces the promotion of Dr. Michael White to President, Research and Development
AInvest Wire · Sep 28, 2026Ideaya Biosciences and Servier announce first patient dosed in optimum-11 global phase 3 registrational trial of darovasertib and crizotinib as adjuvant therapy for subjects with uveal melanoma
AInvest Wire · Sep 9, 2026Ideaya Biosciences, - To initiate phase 3 trial for IDE849 by year-end 2026 in ES-SCLC
AInvest Wire · Aug 31, 2026Ideaya Biosciences announces clinical pact with Genentech
AInvest Wire · Aug 19, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.